I threw out a request on Twitter yesterday for 2013 biotech stock predictions. The response was amazing and overwhelming. Thanks to everyone who contributed. I'll be sure to check back throughout the year to check the accuracy of TheStreet's biotech readers.
If you agree, disagree or feel like something is missing from this list, please share your thoughts and comments below.
TheStreet readers' 2013 biotech stock predictions:
AMRN - still independent, launch sales - they will spend much more on mkting, admin, sales than actual gains from product sales. No NCE/— Sport234a2b (@Sport234a) January 1, 2013
my wildest 2013 prediction : $TRGT will be bought in the low 10s— max (@LTbioinvestor) January 1, 2013
@ adamfeuerstein $IMUC ict-107 offers statistically significant OS— Shitmylabmatesays (@Shtmylabmatesez) January 1, 2013
@ adamfeuerstein my wildest prediction: $CYTK breaks thru $1. benefit in ALS+partner.meets 1ary endpnt in HF— Juan P. Serrate, DVM (@JPZaragoza1) January 1, 2013
@ adamfeuerstein Amrn BO price $23 by April— mimosttr (@trstmomi) January 2, 2013
SRPT - expect FDAyes 4 a NDA filing based on current data, a very tough panel review potential late 13, very volatile stk in 13.— Sport234a2b (@Sport234a) January 1, 2013
Prosensa/GSK - sadly, my leaning is a miss for their DMD P3, my problem is w/enrollment criteria, and countries involved.— Sport234a2b (@Sport234a) January 1, 2013
@ adamfeuerstein $GSK will buy the rest of $FOLD 5-6 range. $INCY will be bid for by several BP's making it the star of the year.— JNV (@JNVcapital) January 1, 2013
@ adamfeuerstein Biotech cos add buy-back provisions in outlicens deals. One co will raise money to exercise; partner will buy the co instead— David Sable (@dbsable) January 1, 2013
@ adamfeuerstein $SGMO and other HIV-elimination (cure) technologies emerge as a threat to $GILD $JNJ $MRK $GSK and others— Martin Shkreli (@MartinShkreli) January 1, 2013
@ adamfeuerstein inflammation platforms become the biotech theme for 2013— Norcaljosh (@norcaljosh) January 1, 2013
.@ adamfeuerstein Mdvn pre-chemo data trumps zytiga by 2 months. Combo trials gives PCA patients an extra 8 months (2014 data?). Dndn dies.— daviesbj (@daviesbj) January 1, 2013
@ adamfeuerstein APPA is the best performer out of all of the he "A" stocks(AMRN, ARNA, ALXA have TERRIBLE launches and stock prices suffer)— Chet Stedman (@ChetStedman5) January 1, 2013
@ adamfeuerstein Mnkd will be the biotech of the year.— Al Marino (@optiontrader78) January 1, 2013
@ adamfeuerstein My prediciton?No matter what biotech I am in, I'm gonna get f----d one way or the other.— TraderNeal (@traderneal) January 1, 2013
@ adamfeuerstein I predict the anti-PD1s will be big successes in multiple solid tumor types. Lung and melanoma in particular. $BMY and $MRK— Chris Ahlstrand (@ahlstrac) January 1, 2013
@ adamfeuerstein Initiation of multiple HCV trials of 2 or 3 drug nuke/2nd gen NS5As/PI combos with treatment duration 6 weeks or less— John Alan Tucker (@JohnTuckerPhD) January 1, 2013
@ adamfeuerstein I predict you are accused of being a hedge fund shill at least 500x in 2013— Stock Jock (@hedgeorbehedged) January 1, 2013
@ adamfeuerstein Some speculative predictions: ACHN does a deal w/ABT or JNJ for 3102. 1625 remains unpartnered.— John Alan Tucker (@JohnTuckerPhD) January 1, 2013More biotech stock prediction Tweets on the next page.
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
Check Out Our Best Services for Investors
David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
Every recommendation goes through 3 layers of intense scrutinyquantitative, fundamental and technical analysisto maximize profit potential and minimize risk.
Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.